Drug intelligence / Profile preview

BMS-986527

Development stage: Phase 1
Lead developer: Bristol Myers Squibb
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

BMS-986527 is an investigational, healthy donor-derived, allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD70. Developed by Juno Therapeutics (a Bristol Myers Squibb company), BMS-986527 is designed to target CD70-expressing tumor cells. It is currently being evaluated in a Phase 1 clinical trial (CA259-0001) as a monotherapy or in combination with nivolumab or cabozantinib for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC).

Targets

CD70 (Cluster of Differentiation 70)

Beyond the preview

Go deeper on BMS-986527.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-986527.